MétaCan
Menu
← Back to cohort
Record W4220951070 · doi:10.1101/2022.03.21.22272544

Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

2022· preprint· en· W4220951070 on OpenAlexaff
Hilary A. Robbins, Karine Alcala, Elham Khodayari Moez, Florence Guida, Sera Thomas, Hana Zahed, Matthew T. Warkentin, Karl Smith-Byrne, Yonathan Brhane, David C. Muller, Demetrius Albanes, Melinda C. Aldrich, Alan A. Arslan, Julie K. Bassett, Christine D. Berg, Qiuyin Cai, Chu Chen, Michael P.A. Davies, Brenda Diergaarde, John K. Field, Neal D. Freedman, Wen‐Yi Huang, Mikael Johansson, Michael Jones, Woon‐Puay Koh, Stephen Lam, Qing Lan, Arnulf Langhammer, Linda M. Liao, Geoffrey Liu, Reza Malekzadeh, Roger L. Milne, Luis M. Montuenga, Thomas E. Rohan, Howard D. Sesso, Gianluca Severi, Mahdi Sheikh, Rashmi Sinha, Xiao‐Ou Shu, Victoria L. Stevens, Martin C. Tammemägi, Lesley F. Tinker, Kala Visvanathan, Ying Wang, Renwei Wang, Stephanie J. Weinstein, Emily White, David Wilson, Jian‐Min Yuan, Xuehong Zhang, Wei Zheng, Christopher I. Amos, Paul Brennan, Mattias Johansson

Bibliographic record

VenuemedRxiv · 2022
Typepreprint
Languageen
FieldMedicine
TopicLung Cancer Diagnosis and Treatment
Canadian institutionsBrock UniversityPrincess Margaret Cancer CentreBC Cancer AgencyInstitute of Cancer ResearchPublic Health OntarioUniversity of TorontoLunenfeld-Tanenbaum Research Institute
FundersNational Cancer InstituteWorld Health OrganizationEuropean Regional Development FundInstituto de Salud Carlos IIICenters for Disease Control and PreventionNational Heart, Lung, and Blood InstituteAmerican Institute for Cancer ResearchCentre International de Recherche sur le CancerLung Cancer Research FoundationU.S. Department of Health and Human ServicesNational Institutes of HealthInstitut National Du Cancer
KeywordsLung cancerMedicineBiomarkerMalignancyNodule (geology)OncologyCancerInternal medicineCohortEtiologyCohort studyBiology

Abstract

fetched live from OpenAlex

The Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) program is an NCI-funded initiative with an objective to develop tools to optimize lung cancer screening. Here, we describe the rationale and design for the Risk Biomarker and Nodule Malignancy projects within INTEGRAL. The overarching goal of these projects is to systematically investigate circulating protein markers to include on a panel for use (i) pre-LDCT, to identify people likely to benefit from screening, and (ii) post-LDCT, to differentiate benign versus malignant nodules. To identify informative proteins, the Risk Biomarker project measured 1,161 proteins in a nested-case control study within 2 prospective cohorts (n=252 lung cancer cases and 252 controls) and replicated associations for a subset of proteins in 4 cohorts (n=479 cases and 479 controls). Eligible participants had any history of smoking and cases were diagnosed within 3 years of blood draw. The Nodule Malignancy project measured 1,077 proteins among participants with a heavy smoking history within 4 LDCT screening studies (n=425 cases within 5 years of blood draw, 398 benign-nodule controls, and 430 nodule-free controls). The INTEGRAL panel will enable absolute quantification of 21 proteins. We will evaluate its lung cancer discriminative performance in the Risk Biomarker project using a case-cohort study including 14 cohorts (n=1,696 cases and 2,926 subcohort representatives), and in the Nodule Malignancy project within 5 LDCT screening studies (n=675 cases, 648 benign-nodule controls, and 680 nodule-free controls). Future progress to advance lung cancer early detection biomarkers will require carefully designed validation, translational, and comparative studies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.532
metaresearch head score (Gemma)0.506
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Methods · Consensus signal: Methods
Teacher disagreement score0.532
Threshold uncertainty score0.578

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.5320.506
Meta-epidemiology (narrow)0.0020.003
Meta-epidemiology (broad)0.0030.005
Bibliometrics0.0030.004
Science and technology studies0.0040.006
Scholarly communication0.0060.003
Open science0.0070.009
Research integrity0.0040.006
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.136
GPT teacher head0.437
Teacher spread0.302 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designNot applicable
Domainnot available
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2022
Admission routes1
Has abstractyes

Explore more

Same venuemedRxiv→Same topicLung Cancer Diagnosis and Treatment→French-language works237,207→